Similar Natural Products in NPASS
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC473035 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 2624 |
0.1-0.2 | 21956 |
0.2-0.3 | 5191 |
0.3-0.4 | 893 |
0.4-0.5 | 178 |
0.5-0.6 | 28 |
0.6-0.7 | 11 |
0.7-0.8 | 6 |
0.8-0.85 | 1 |
0.85-0.9 | 0 |
0.9-0.95 | 1 |
0.95-1 | 0 |
  Similar Clinical/Approved Drugs
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC473035 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 184 |
0.1-0.2 | 5604 |
0.2-0.3 | 2705 |
0.3-0.4 | 520 |
0.4-0.5 | 91 |
0.5-0.6 | 39 |
0.6-0.7 | 7 |
0.7-0.8 | 10 |
0.8-0.85 | 1 |
0.85-0.9 | 0 |
0.9-0.95 | 0 |
0.95-1 | 0 |
Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8421 |
Intermediate Similarity |
NPD2707 |
Clinical (unspecified phase) |
0.7778 |
Intermediate Similarity |
NPD5384 |
Approved |
0.7778 |
Intermediate Similarity |
NPD5385 |
Approved |
0.7619 |
Intermediate Similarity |
NPD390 |
Approved |
0.7619 |
Intermediate Similarity |
NPD718 |
Approved |
0.75 |
Intermediate Similarity |
NPD3734 |
Approved |
0.75 |
Intermediate Similarity |
NPD2706 |
Approved |
0.75 |
Intermediate Similarity |
NPD2705 |
Approved |
0.7297 |
Intermediate Similarity |
NPD2274 |
Approved |
0.7297 |
Intermediate Similarity |
NPD2275 |
Approved |
0.7143 |
Intermediate Similarity |
NPD2273 |
Clinical (unspecified phase) |
0.6939 |
Remote Similarity |
NPD3722 |
Approved |
0.6939 |
Remote Similarity |
NPD3721 |
Approved |
0.6842 |
Remote Similarity |
NPD1156 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD2276 |
Clinical (unspecified phase) |
0.6579 |
Remote Similarity |
NPD401 |
Approved |
0.6154 |
Remote Similarity |
NPD4839 |
Approved |
0.6087 |
Remote Similarity |
NPD9458 |
Approved |
0.5882 |
Remote Similarity |
NPD4834 |
Discontinued |
0.587 |
Remote Similarity |
NPD9227 |
Discontinued |
0.58 |
Remote Similarity |
NPD5379 |
Clinical (unspecified phase) |
0.5714 |
Remote Similarity |
NPD2271 |
Phase 3 |
0.5686 |
Remote Similarity |
NPD396 |
Approved |
0.5686 |
Remote Similarity |
NPD395 |
Approved |
0.5652 |
Remote Similarity |
NPD1463 |
Clinical (unspecified phase) |
0.5641 |
Remote Similarity |
NPD9465 |
Approved |
0.561 |
Remote Similarity |
NPD8948 |
Approved |
0.56 |
Remote Similarity |
NPD9459 |
Approved |
0.56 |
Remote Similarity |
NPD874 |
Approved |
0.56 |
Remote Similarity |
NPD9460 |
Approved |
0.56
|
Remote Similarity |
NPD872 |
Approved |